Interpretation of 2-[F-18]FDG PET/CT in Hodgkin lymphoma patients treated with immune checkpoint inhibitors - Université de Rennes Accéder directement au contenu
Article Dans Une Revue European Radiology Année : 2022

Interpretation of 2-[F-18]FDG PET/CT in Hodgkin lymphoma patients treated with immune checkpoint inhibitors

Résumé

The development of immunotherapy has revolutionized cancer treatment, improving the outcome and survival of many patients. Immune checkpoint inhibitors (ICIs), the most common form of immunotherapy, use antibodies to restore T-cells' anti-tumor activity. Immune checkpoint inhibitors are gaining ground in the therapeutic strategy across various cancers. Although widely used in solid tumors, ICIs have shown remarkable efficacy in patients with Hodgkin lymphoma. 2-[F-18]Fluoro-2-deoxy-D-glucose (FDG)-positron emission tomography (PET)/CT is the gold standard to stage and monitor responses in Hodgkin lymphoma. This article reviewed the use of 2-[F-18]FDG-PET/CT in patients with Hodgkin lymphoma treated with ICI, focusing on image interpretation for response monitoring and detecting adverse events.
Fichier principal
Vignette du fichier
Manson et al -2022-Interpretation of 2-[F-18]FDG PETCT in Hodgkin lymphoma patients treated with.pdf (1.01 Mo) Télécharger le fichier
Manson_330_2022_8669_MOESM1_ESM.pdf (57.9 Ko) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)
Commentaire : Version acceptée mais certaines marques de révision n'ont pu être supprimées

Dates et versions

hal-03665222 , version 1 (30-09-2022)

Identifiants

Citer

Guillaume Manson, Amaeshi Chukwunonye Lemchukwu, Fatima-Zohra Mokrane, Egesta Lopci, Nicolas Aide, et al.. Interpretation of 2-[F-18]FDG PET/CT in Hodgkin lymphoma patients treated with immune checkpoint inhibitors. European Radiology, 2022, 32, pp.6536-6544. ⟨10.1007/s00330-022-08669-8⟩. ⟨hal-03665222⟩
181 Consultations
200 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More